WO2012150890A1 - Composition antibactérienne - Google Patents
Composition antibactérienne Download PDFInfo
- Publication number
- WO2012150890A1 WO2012150890A1 PCT/SE2012/000056 SE2012000056W WO2012150890A1 WO 2012150890 A1 WO2012150890 A1 WO 2012150890A1 SE 2012000056 W SE2012000056 W SE 2012000056W WO 2012150890 A1 WO2012150890 A1 WO 2012150890A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- silver
- lipid
- silicone oil
- aliphatic alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 10
- 150000002632 lipids Chemical class 0.000 claims abstract description 76
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000004332 silver Substances 0.000 claims abstract description 42
- 229910052709 silver Inorganic materials 0.000 claims abstract description 42
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000012528 membrane Substances 0.000 claims abstract description 21
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 17
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000002245 particle Substances 0.000 claims abstract description 5
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 4
- 238000009835 boiling Methods 0.000 claims abstract description 4
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 229920002545 silicone oil Polymers 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 206010052428 Wound Diseases 0.000 claims description 14
- 208000027418 Wounds and injury Diseases 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 9
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 229940018602 docusate Drugs 0.000 claims description 5
- 238000009834 vaporization Methods 0.000 claims description 5
- 230000008016 vaporization Effects 0.000 claims description 5
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 claims description 4
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 claims description 4
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 4
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 102000058004 human PTH Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 238000002525 ultrasonication Methods 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 2
- 229950006323 angiotensin ii Drugs 0.000 claims description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical class C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 2
- 102000014509 cathelicidin Human genes 0.000 claims description 2
- 108060001132 cathelicidin Proteins 0.000 claims description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 2
- 150000003378 silver Chemical class 0.000 claims description 2
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
- -1 siloxanes Chemical class 0.000 abstract description 10
- 239000003921 oil Substances 0.000 abstract description 8
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 13
- 229910001961 silver nitrate Inorganic materials 0.000 description 11
- 235000007319 Avena orientalis Nutrition 0.000 description 8
- 244000075850 Avena orientalis Species 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- QMIYKBFAWPSBQJ-UHFFFAOYSA-N 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid;silver Chemical compound [Ag].CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC QMIYKBFAWPSBQJ-UHFFFAOYSA-N 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- QZXMUPATKGLZAP-DXLAUQRQSA-N [(2S)-1-hexadecanoyloxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QZXMUPATKGLZAP-DXLAUQRQSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 150000002313 glycerolipids Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- YRSQDSCQMOUOKO-KVVVOXFISA-M silver;(z)-octadec-9-enoate Chemical compound [Ag+].CCCCCCCC\C=C/CCCCCCCC([O-])=O YRSQDSCQMOUOKO-KVVVOXFISA-M 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ONBWNNUYXGJKKD-UHFFFAOYSA-N 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid;sodium Chemical compound [Na].CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC ONBWNNUYXGJKKD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UJDBFRUUHDPAEC-UHFFFAOYSA-N 2-[(Z)-octadec-9-enyl]propane-1,2,3-triol Chemical compound C(CCCCCCCC=C/CCCCCCCC)C(CO)(O)CO UJDBFRUUHDPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- ADLVDYMTBOSDFE-UHFFFAOYSA-N 5-chloro-6-nitroisoindole-1,3-dione Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC2=C1C(=O)NC2=O ADLVDYMTBOSDFE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000630627 Diodella Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- FYBYQXQHBHTWLP-UHFFFAOYSA-N bis(silyloxysilyloxy)silane Chemical class [SiH3]O[SiH2]O[SiH2]O[SiH2]O[SiH3] FYBYQXQHBHTWLP-UHFFFAOYSA-N 0.000 description 1
- 125000000837 carbohydrate group Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- QZRSVBDWRWTHMT-UHFFFAOYSA-M silver;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound [Ag+].OC(=O)CC(O)(C([O-])=O)CC(O)=O QZRSVBDWRWTHMT-UHFFFAOYSA-M 0.000 description 1
- DJXAJTDFRRFQDI-UHFFFAOYSA-N silyloxy(silyloxysilyloxysilyloxysilyloxy)silane Chemical class [SiH3]O[SiH2]O[SiH2]O[SiH2]O[SiH2]O[SiH3] DJXAJTDFRRFQDI-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Definitions
- the present invention relates to an antibacterial composition capable of forming a layer comprising a pharmacologically effective amount of an antibacterial agent, to a method of manufacture of the composition and to a method of applying it on a wound.
- Antibacterial compositions for topical administration are known in the art. Their administration to the skin or to a wound, in particular to skin of which the integrity has been jeopardized by, for instance, inflammation or irritation, is however still problematic.
- the physical form of silver incorporation ranges from elemental metallic silver nanoparticles to salts of varying sparing solubility in water. In all instances, however, it is the silver ion species, produced by oxidation or dissolution that is believed to be the antimicrobially active agent (Texter J et al., Bactericidal silver ion delivery into hydrophobic coatings with surfactants. J Ind Microbiol Biotechnol [2007) 34: 571-575].
- composition is easily applicable to the skin or the wound so as to form a coherent layer on it.
- Still another object of the invention is to provide such a composition that does not cause swelling when applied to the skin.
- a further object of the invention is to provide such a composition that does not give a burning feeling when applied to the skin.
- compositions of the aforementioned kind comprising or substantially consisting of an oily lipid, in particular a polar oily lipid, a volatile silicone oil, a silver source, and optionally a lower aliphatic alcohol.
- the silver source is present in dissolved and/or suspended form in the composition.
- the silver source comprises silver in elemental and/or ionic form capable of exerting an antimicrobial effect. It is preferably selected from the group consisting of silver salt, in particular salt of monovalent silver (Ag + X ), silver complex, in particular organic silver complex, colloidal silver, silver particles, in particular silver
- nanoparticles and their mixtures.
- the silver source is an inorganic silver salt such as silver nitrate or an organic silver salt such as silver dihydrogen citrate.
- the silver source is monovalent silver ion stabilized by ⁇ -complex formation with a ⁇ -bond of cis- configuration comprised by an unsaturated chain of an oily lipid, such as a mono- or polyunsaturated aliphatic chain, in particular a mono- or polyunsaturated aliphatic chain of a polar oily lipid such as dioleoylphosphatidylcholine (DOPC) and
- DOPC dioleoylphosphatidylcholine
- dioleoylphosphatidylethanolamine DOPE
- examples of other polar lipids useful in the invention include monooleoylglycerol and soy bean lecithin.
- the silver source is a complex between silver ion and a thiol group-containing compound.
- Complexes of this kind are disclosed in EP 727 427 Al, which is incorporated herein by reference.
- the silver source is a complex between silver ion and a N-heterocyclic carbene.
- Complexes of this kind are disclosed in US 2008/0267867 Al, which is incorporated herein by reference.
- the silver source is a monovalent silver salt of an anionic surfactant or detergent such as l,4-bis(2- ethylhexyl) sulphosuccinate (dioctyl sulfosuccinate or docusate ⁇ .
- an anionic surfactant or detergent such as l,4-bis(2- ethylhexyl) sulphosuccinate (dioctyl sulfosuccinate or docusate ⁇ .
- the silver source is finely dispersed elemental silver, such as of an average particle size of less than 20 ⁇ , in particular of less than 5 ⁇ , and silver nanoparticles, such as of a size of 100 nanometers or less.
- the composition of the invention consists of a single phase.
- the low viscosity of the composition allows administration of the composition to the skin or a wound by spraying.
- the composition forms a coherent layer from which the solvent evaporates or, in respect of the alcohol, if present, may be partially absorbed by the skin or tissue. Evaporation of the volatile components transforms the initially formed layer into a residual layer of oily lipid, in particular of oily polar lipid, and silver source.
- the composition can comprise other antimicrobial agents, such as antimicrobial peptides or peptides promoting wound healing.
- Preferred wound healing promoting peptides of the invention include angiotensin II, a wound healing fragment, analog or derivative of angiotensin II, human parathyroid hormone, a wound healing fragment, analog or derivative of human parathyroid hormone, cathelicidin polypeptide LL37, a wound healing fragment, analog or derivative of cathelicidin polypeptide LL37.
- a wound of which the healing can be promoted by the composition of the invention may, for instance, be a shallow or deep wound formed by incision or other damage of the skin such as by abrasion or a wound caused by burning, such as skin damaged by burning, but also a bone fracture.
- the present invention is based on the finding that a particular class of solvents, volatile silicone oils, optionally in combination with a lower aliphatic alcohol, are particularly useful in formulating a composition comprising a polar lipid, suitable for incorporation of the antimicrobial agent of the invention.
- a particular class of solvents, volatile silicone oils, optionally in combination with a lower aliphatic alcohol are particularly useful in formulating a composition comprising a polar lipid, suitable for incorporation of the antimicrobial agent of the invention.
- the composition of the invention forms an instable polar lipid layer from which the volatile silicone oil and, if present, the lower aliphatic alcohol, evaporate readily, leaving a stable oily polar lipid layer substantially consisting of polar lipid comprising the silver source of the invention.
- the low viscosity of the composition of the invention seems, i.a., to be due to the inability of polar lipids to form lyotropic liquid crystals, such as lamellar hexagonal and various cubic phases of high viscosity.
- the composition of the invention is clear and of low viscosity even at concentrations of polar lipid as high as 20 % by weight.
- polar lipid compositions corresponding to those of the invention but in which the silicone oil component is substituted by a corresponding weighed amount of water are slightly viscous dispersions at low membrane lipid concentrations or thick gels at 20 % by weight of membrane lipid in respect of the composition, the highest membrane lipid concentration tested;
- the high viscosity of the composition comprising 20 % by weight of membrane lipid does not allow it to be administered by spraying.
- Silicone oils of pharmaceutical grade useful in the invention are known in the art.
- useful silicone oils include dekamethylcyclopentasiloxane [Dow Corning ® 345 Fluid and cyclomethicone 5-NF) and dodekamethylcyclohexasiloxane [Dow Corning ® 246 Fluid). While pentasiloxanes and hexasiloxanes are preferred, terra-, hepta-, and octasiloxanes are also potentially useful.
- the silicone oils of the invention can be used in pure form or in admixture.
- one or more methyl groups of a siloxane can be substituted by lower alkyl, in particular by ethyl, propyl or isopropyl.
- Siloxanes partially or fully substituted by lower trifluoroalkyl, in particular trifluoromethyl and pentafluoroethyl, are also useful in the invention.
- silicone oil in the invention is determined by its volatility.
- a silicone oil of the invention evaporates easily. This is due to the low heat of vaporization of this class of compounds.
- a silicone oil having a heat of vaporization (kj/kg) at 25 °C of from about 100 kj/kg to about 300 kj/kg, more preferred of from about 120 kj/kg to about 200 kj/kg are particularly useful. Even more preferred is a silicone oil having a heat of vaporization of from 140 kj/kg to about 180 kj/kg at 25 °C.
- the silicone oil of the invention provides the composition of the invention with at least the following advantageous features: i] the ability to incorporate high contents of polar lipid material; / ' ) the formation of thermodynamically stable solutions; Hi] the low viscosity of the solutions formed making them suitable for, e.g., spraying, dropping, painting or instilling.
- the lower aliphatic alcohol of the invention is a C 2 to C 4 alcohol or a mixture of such alcohols, in particular an alcohol selected from C 2 to C3 alcohol and tert- butanol. Particularly preferred is ethanol. Also useful in the invention is a partially or fully fluorinated Ci to C 4 alcohol, a mixture of such alcohols, and a mixture of Ci to C 4 alcohol and a partially or fully fluorinated Ci to C 4 alcohol.
- the C 2 to C 4 alcohol may comprise 1,2-propanediol, and/or glycerol, in an amount of up to 20 % or 50 % by weight of the C 2 to C 4 alcohol.
- the oily polar lipid of the invention can be described as a lipid capable of interaction with water (as defined in D. Small, The Physical Chemistry of Lipids. Plenum Press 1986, section 4.3), for example formed of membrane lipid, that is, lipid
- Membrane lipids contain a polar, hydrophilic head group and one or more lipophilic hydrocarbon chains. This combination makes the membrane lipid molecules amphipathic and enables their association with water and with oil. Membrane lipids can be classified according to their chemical structure, which is a function of how the polar head group is linked to the lipophilic chains. Sphingolipids (linked by sphingosine) and glycerolipids [linked by glycerol) are the two main groups. Depending on the characteristics of the polar head group sphingolipids and glycerolipids can be further classified as phospholipids comprising a phosphate ester head group and glycolipids comprising a carbohydrate head group.
- membrane lipids are sometimes called, for instance, galactolipids, which are glycerolipids with galactose in the polar head group.
- galactolipids which are glycerolipids with galactose in the polar head group.
- Examples of common membrane lipids are phosphatidylcholine (PC),
- Membrane lipids of interest can be extracted from, for example, egg yolk (egg lecithin), milk and dairy products, soybeans (soy lecithin), other oil crops, oat kernels, and other cereal and grains. These extracts can be further treated to obtain, for instance, PC from soy beans and galactolipids from oats.
- Preferred polar lipids are galactolipids, in particular galactolipids from oat kernels, or phospholipids from soybeans (soy lecithin or soy-PC).
- Synthetic or semi-synthetic polar lipids and membrane lipid analogues based on a carbohydrate or phosphate ester moiety are also comprised by membrane lipids of the invention.
- Examples of synthetic polar lipids comprise dioleoylphosphatidylcholine and dioleoylphosphatidylethanolamine.
- Other lipids capable of interaction with water are monoglycerides, for example monooleylglycerol.
- the oily lipid of the invention can be a polar or non-polar lipid, comprising a side chain with a ⁇ -bond of cis-configuration.
- the oily lipid of the invention comprises an unsaturated mono-, di-, or triglyceride, in particular one comprising one or more mono-unsaturated acyl residues of cis-configuration, most particularly oleic acid.
- the oily lipid of the invention can be obtained from natural sources or be of synthetic or semi-synthetic origin.
- the use of a lower aliphatic alcohol such as ethanol for the dissolution of the oily polar lipid of the invention is particularly useful with a lipid with a low chain- melting temperature.
- the chain-melting temperature is the temperature at which the acyl chains of the membrane lipid undergo a phase transition in an excess of water, from a solid-like state to a melted or liquid-like state.
- Lipoid S75, Lipoid S45, Phospholipon 50, Lipoid SlOO, and DOPC all have chain-melting temperatures below 0°C and can thus be readily dissolved in absolute ethanol at concentrations up to 50 % by weight and even higher.
- the polar lipid in particular a membrane lipid mixture such as lecithin or fractionated oat oil, may alternatively be dissolved in a lower aliphatic alcohol and then diluted with a volatile silicone oil, resulting in a low-viscous, sprayable, homogenous liquid.
- Fractionated oat oil is obtained from crude oat oil and is enriched in polar lipids.
- non-polar lipids such as triacylglycerols and diacylglycerols
- polar lipids such as phospholipids and glycolipids.
- the content of digalactosyldiacylglycerol in fractionated oat oil is about 20 % by weight.
- Suitable fractionated oat oils are disclosed, for instance, in WO 99/44585 Al.
- Lipids like phosphatidylethanolamine and dioleylphosphatidylethanol- amine can also be used as the polar lipid component of the invention as such or in admixture with other polar lipids.
- DOPE has a chain-melting temperature of -16°C in water and can be dissolved in absolute ethanol at 50 % by weight or higher at elevated temperatures (>60°C). Such solution can be diluted with volatile silicone oil such as DC 345, resulting in a clear, low-viscous liquid.
- the antimicrobial composition of the invention is preferably substantially water-free, in particular has a water content of less than 5 % by weight, preferably of less than 2 % or 1 % by weight and even less than 0.5 % by weight or 0.2 % by weight.
- the antimicrobial composition of the invention comprises from 10 % by weight to 30 % by weight of membrane lipid, from 10 % by weight to 30 % by weight of ethanol, from 0.01 % by weight to 5 % by weight of antimicrobial agent, the remainder being volatile silicone oil, with the proviso that the content of volatile silicone oil is 40 % by weight or more.
- Silver l,4-bis(2-ethylhexyl) sulphosuccinate was prepared according to the following procedure which is a modification of the method used by Petit et al., J Phys Chem 1993, 97, 12974-12983.
- a slurry of 6.7 g of Dowex Monosphere M-31 strongly acidic cation exchange resin in ca 20 ml of deionized water is applied to a 25 x 150 mm glass column. The resin is regenerated by elution with 10 ml of 1.0 M HCl and washed with 10 ml of deionized water followed by 10 ml of methanol/water 1:2 (v/v).
- 1,4-bis (2 -ethylhexyl) sulphosuccinate [222 mg) is dissolved in 3.0 ml of methanol/water 1:2 (v/v) and applied to the column. 1,4-Bis(2- ethylhexyl) sulphosuccinic acid is eluted by 7 ml of methanol/water 1:2 (v/v).
- a slurry of 13,5 g of Lewatit CNP 105 weakly acidic cation exchange resin in about 20 ml of deionized water is applied to a second 25 x 150 mm glass column and washed with 10 ml of deionized water, followed by 10 ml of methanol/water 1:2 (v/v).
- Silver nitrate (164 mg) is dissolved in 5 ml of methanol/water 1:2 (v/v) and applied to the second column.
- the resin is washed by 5 ml of deionized water followed by 10 ml of methanol/water 1:2 (v/v).
- the solution of l,4-bis(2-ethylhexyl) sulphosuccinic acid was applied to the second column, and silver 1,4-bis (2 -ethylhexyl) sulphosuccinate is eluted by 23 ml of methanol/water 1:2 (v/v).
- the eluate is evaporated, resulting in 83.3 mg of a white semisolid residue.
- compositions according to the invention comprising silver 1,4-bis (2 -ethylhexyl) sulphosuccinate were prepared by mixing a alcoholic solution of docusate silver with volatile silicone oil (DC 245, DC 246 or DC 345) and polar oily lipid by ultrasonication.
- DC 245, DC 246 or DC 3405 volatile silicone oil
- polar oily lipid by ultrasonication.
- composition of the invention comprising Ag + / olefin complex.
- Silver nitrate (13.7 mg) was dissolved in 4.73 g of ethanol.
- the silver nitrate solution (1.50 g) was then mixed with DC 345, resulting in a clear homogenous solution.
- DOPE (48.8 mg) was dissolved in the mixture by ultrasonication.
- the thus obtained mixture contains 0.07 % by weight of silver nitrate, 2.4 % by weight of DOPE, 24.3 % by weight of ethanol and 73.2 % by weight of DC 345.
- the concentration of silver nitrate in the non-volatile part of the composition is 2.8 % by weight.
- the presence of Ag + /olefin complex was demonstrated by 13 C NMR spectroscopy (Table 2).
- a solution suitable for NMR analysis was prepared in the following manner. Silver nitrate (1.08 mg) and 15.7 mg of DOPE was dissolved in 90.0 mg of methanol-d 4 in a vial by ultrasonic agitation to form a first mixture. In another vial 131.8 mg of chloroform-di was mixed with 516.1 mg of DC 345 to form a second mixture. The first and second mixtures were combined and ultrasonicated. The resulting clear colourless solution was transferred to a 0.5 mm ID NMR tube.
- composition A Composition B
- a pre-weighed amount of silver nitrate was dissolved in ethanol.
- To the solution was added 50 % (w/w) of phospholipid.
- Complete dissolution of the phospholipid in the ethanolic solution was accomplished by short ultrasonication in a bath-type sonicator at about 40 °C.
- the resulting clear yellow solutions were diluted with silicone oil and stored in air-tight glass vials at room temperature.
- Silver nanoparticles prepared by the method of R Das et al., Preparation of Silver Nanoparticles and Their Characterization. AZojon, Journal of Nanotechnology Online, DOI: 10.2240/azojono0129
- a pre-weighed amount of silver oleate was dissolved in ethanol, then phospholipid was added to the ethanolic solution. After treatment in a bath-type sonicator at about 35°C, a clear solution was obtained. The solution was diluted with the volatile silicone oil and the resulting clear, colourless solution was stored in an airtight glass vial at room temperature.
- Table 3 Presented in Table 3 are data on miscibility of ethanolic phospholipid solutions with either volatile silicone oil or water. The mixtures with a low content of
- PL/ethanol in the silicone oil had a clear appearance immediately after preparation, but separated within a month at room temperature.
- the formulation with a concentration of PL/ethanol of 20 % was miscible with the volatile silicone oil, did not change in appearance during this time period and can thus be considered to be physically stable.
- the phospholipid of Table 3 is Lipoid S75 manufactured by Lipoid GmbH,
- This phospholipid material from soybean contains about 68 -
- PC phosphatidylcholine
- suitable phospholipid materials are, for example, Lipoid S45, Phospholipon 50, and Lipoid S100, all made from soybean and manufactured by Lipoid GmbH, covering a range of PC content of about 50 % up to 100 %.
- Further useful phospholipids are synthetic dimyristoylphosphatidylcholine (DMPC), dioleylphosphatidylcholine (DOPC) and dipalmitoylphosphatidylcholine (DPPC).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition antibactérienne formant une couche lipidique qui comprend une huile de silicone volatile, un lipide gras, une source d'argent, et facultativement un alcool aliphatique en C2-C4. La source d'argent est choisie dans le groupe constitué d'un sel d'argent (Ag+X-), d'argent colloïdal, d'un complexe d'argent, de particules d'argent, de nanoparticules d'argent, et de leurs mélanges. La présente invention concerne en outre un procédé de formation de la couche lipidique sur la peau ou sur une plaie, et un procédé de fabrication de la composition. Les ingrédients préférés comprennent les siloxanes, notamment le décaméthylcyclopentasiloxane et le dodécaméthylcyclohexasiloxane, avec un point d'ébullition défini, et un lipide gras polaire, par exemple, un lipide membranaire tel qu'un phospholipide, un glycolipide ou un sphingolipide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1100341 | 2011-05-02 | ||
SE1100341-5 | 2011-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012150890A1 true WO2012150890A1 (fr) | 2012-11-08 |
Family
ID=47107946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2012/000056 WO2012150890A1 (fr) | 2011-05-02 | 2012-04-20 | Composition antibactérienne |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012150890A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014178789A1 (fr) * | 2013-05-03 | 2014-11-06 | Lipidor Ab | Composition topique et véhicule pour l'administration de principes actifs pharmaceutiques ou cosmétiques |
WO2015072910A1 (fr) * | 2013-11-14 | 2015-05-21 | Lipidor Ab | Compositions topiques pharmaceutiques, cosmétiques et désinfectantes comprenant de la phosphatidylcholine |
WO2015120316A1 (fr) * | 2014-02-07 | 2015-08-13 | Trevena, Inc. | Formes cristallines et amorphes d'un effecteur bêta-arrestine |
CN106109351A (zh) * | 2016-08-23 | 2016-11-16 | 广州洁康卫生用品有限公司 | 一种杀菌修护清洗剂、制备方法及其应用 |
US9534017B2 (en) | 2008-12-29 | 2017-01-03 | Trevena, Inc. | Beta-arrestin effectors and compositions and methods of use thereof |
US9611293B2 (en) | 2014-05-19 | 2017-04-04 | Trevena, Inc. | Synthesis of beta-arrestin effectors |
US10278395B2 (en) | 2013-03-11 | 2019-05-07 | North Carolina State University | Functionalized environmentally benign nanoparticles |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5738859A (en) * | 1997-01-17 | 1998-04-14 | Abbe Cosmetic Group International, Inc. | Cosmetic composition |
EP1066825A1 (fr) * | 1999-06-17 | 2001-01-10 | The Procter & Gamble Company | Produit antimicrobien pour les soins du corps |
US20030170194A1 (en) * | 2000-05-19 | 2003-09-11 | Ralf Piotrowiak | Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid |
US20040234474A1 (en) * | 2001-07-24 | 2004-11-25 | Alvin Berlat | Topical pharmaceutical formulation |
WO2005023213A1 (fr) * | 2003-08-29 | 2005-03-17 | Bio-Gate Ag | Produit de soin corporel contenant des particules poreuses d'argent |
US20060211820A1 (en) * | 2005-03-18 | 2006-09-21 | Jonn Jerry Y | Liquid coating compositions |
US20060246149A1 (en) * | 2003-04-18 | 2006-11-02 | Herwig Buchholz | Antimicrobial pigments |
US20070149448A1 (en) * | 2001-01-29 | 2007-06-28 | Mona Stahle-Backdahl | Use of the cathelicidin ll-37 and dervicaties thereof for would healing |
KR20090099456A (ko) * | 2008-03-17 | 2009-09-22 | (주)에이씨티 | 은 코팅층 함유 실리카 나노분말, 그의 제조방법 및 이를 포함하는 화장료용 조성물 |
-
2012
- 2012-04-20 WO PCT/SE2012/000056 patent/WO2012150890A1/fr active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5738859A (en) * | 1997-01-17 | 1998-04-14 | Abbe Cosmetic Group International, Inc. | Cosmetic composition |
EP1066825A1 (fr) * | 1999-06-17 | 2001-01-10 | The Procter & Gamble Company | Produit antimicrobien pour les soins du corps |
US20030170194A1 (en) * | 2000-05-19 | 2003-09-11 | Ralf Piotrowiak | Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid |
US20070149448A1 (en) * | 2001-01-29 | 2007-06-28 | Mona Stahle-Backdahl | Use of the cathelicidin ll-37 and dervicaties thereof for would healing |
US20040234474A1 (en) * | 2001-07-24 | 2004-11-25 | Alvin Berlat | Topical pharmaceutical formulation |
US20060246149A1 (en) * | 2003-04-18 | 2006-11-02 | Herwig Buchholz | Antimicrobial pigments |
WO2005023213A1 (fr) * | 2003-08-29 | 2005-03-17 | Bio-Gate Ag | Produit de soin corporel contenant des particules poreuses d'argent |
US20060211820A1 (en) * | 2005-03-18 | 2006-09-21 | Jonn Jerry Y | Liquid coating compositions |
KR20090099456A (ko) * | 2008-03-17 | 2009-09-22 | (주)에이씨티 | 은 코팅층 함유 실리카 나노분말, 그의 제조방법 및 이를 포함하는 화장료용 조성물 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9534017B2 (en) | 2008-12-29 | 2017-01-03 | Trevena, Inc. | Beta-arrestin effectors and compositions and methods of use thereof |
US10278395B2 (en) | 2013-03-11 | 2019-05-07 | North Carolina State University | Functionalized environmentally benign nanoparticles |
WO2014178789A1 (fr) * | 2013-05-03 | 2014-11-06 | Lipidor Ab | Composition topique et véhicule pour l'administration de principes actifs pharmaceutiques ou cosmétiques |
CN105682686A (zh) * | 2013-05-03 | 2016-06-15 | 立普妥公司 | 用于给药的运载体和局部组合物 |
WO2015072910A1 (fr) * | 2013-11-14 | 2015-05-21 | Lipidor Ab | Compositions topiques pharmaceutiques, cosmétiques et désinfectantes comprenant de la phosphatidylcholine |
WO2015120316A1 (fr) * | 2014-02-07 | 2015-08-13 | Trevena, Inc. | Formes cristallines et amorphes d'un effecteur bêta-arrestine |
US20150225461A1 (en) * | 2014-02-07 | 2015-08-13 | Trevena, Inc. | Crystalline and amorphous forms of a beta-arrestin effector |
US9518086B2 (en) | 2014-02-07 | 2016-12-13 | Trevena, Inc. | Crystalline and amorphous forms of a β-arrestin effector |
US9611293B2 (en) | 2014-05-19 | 2017-04-04 | Trevena, Inc. | Synthesis of beta-arrestin effectors |
CN106109351A (zh) * | 2016-08-23 | 2016-11-16 | 广州洁康卫生用品有限公司 | 一种杀菌修护清洗剂、制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012150890A1 (fr) | Composition antibactérienne | |
JP6162763B2 (ja) | 生体の表面に投与するための脂質層形成性組成物 | |
KR20120129864A (ko) | 소포성 제형 | |
HU221432B (en) | Lipophilic carrier preparations | |
JP2003026625A (ja) | 還元型補酵素qの安定な溶液 | |
CN110870857A (zh) | 改善的包含姜黄素的复合物和组合物 | |
WO2012150892A1 (fr) | Traitement du psoriasis | |
WO2021192861A1 (fr) | Liquide ionique, solvant, préparation et agent pouvant être absorbé par voie transdermique | |
EP2158915B1 (fr) | Acyl- glycérophospholipides destinés au traitement des effets secondaires du cancer | |
CA2455226A1 (fr) | Compositions comprenant une emulsion aqueuse contenant un acide linoleique conjugue | |
DE112013002492T5 (de) | Vesikuläre Formulierungen, Verwendungen und Verfahren | |
DE112013002488T5 (de) | Vesikuläre Formulierungen, Kits und Verwendungen | |
JP2008088133A (ja) | ベシクル組成物、及びそれを用いた皮膚外用剤 | |
JP2023522146A (ja) | ホスファチジルコリンを含むヒマワリリン脂質組成物 | |
US20100016269A1 (en) | Composition of plant sterol and phosphatidylcholine and method for producing the same | |
WO2023286120A1 (fr) | Agent d'absorption percutanée | |
JPH02203928A (ja) | 界面活性作用の強化されたグリセロ燐脂質組成物 | |
EP2120873B1 (fr) | Forme posologique topique comprenant des composés de glycérol trisubstitué | |
EP2231119A1 (fr) | Mousses pharmaceutiques | |
JP2023135125A (ja) | ベシクル組成物 | |
WO2003020318A1 (fr) | Composition d'emulsion eau dans l'huile pour application locale | |
WO2019230964A1 (fr) | Composition d'émulsion de type huile dans eau conditionnée | |
JPH01307438A (ja) | 安全でかつ高度な界面活性を有する脂質組成物 | |
EP3579829A1 (fr) | Efficacité à long terme du traitement d'une maladie du foie par epa et dha | |
JPH04108732A (ja) | Paf拮抗剤含有脂肪乳剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12779789 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12779789 Country of ref document: EP Kind code of ref document: A1 |